Go Pro
→ BlackRock and Vanguard already own THIS (From Monument Traders Alliance) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$84.95
$79.85
$30.25
▼
$85.01
$9.01B0.082.43 million shsN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$246.81
$249.33
$123.88
▼
$266.38
$16.02B0.361.04 million shs321,867 shs
Viatris Inc. stock logo
VTRS
Viatris
$16.88
$16.78
$9.43
▼
$18.39
$19.39B0.898.63 million shs5.73 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$75.70
-0.1%		$75.58
$71.00
▼
$155.15
$31.33B0.735.02 million shs4.17 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
0.00%0.00%+1.03%+142.92%+138.56%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%-1.54%-3.80%+7.69%+90.59%
Viatris Inc. stock logo
VTRS
Viatris
0.00%+2.24%+2.74%+4.20%+60.76%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%-1.68%+4.37%-7.74%-50.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$84.95
$79.85
$30.25
▼
$85.01
$9.01B0.082.43 million shsN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$246.81
$249.33
$123.88
▼
$266.38
$16.02B0.361.04 million shs321,867 shs
Viatris Inc. stock logo
VTRS
Viatris
$16.88
$16.78
$9.43
▼
$18.39
$19.39B0.898.63 million shs5.73 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$75.70
-0.1%		$75.58
$71.00
▼
$155.15
$31.33B0.735.02 million shs4.17 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
0.00%0.00%+1.03%+142.92%+138.56%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%-1.54%-3.80%+7.69%+90.59%
Viatris Inc. stock logo
VTRS
Viatris
0.00%+2.24%+2.74%+4.20%+60.76%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%-1.68%+4.37%-7.74%-50.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.24
Hold$81.00-4.65% Downside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
3.00
Buy$285.4415.65% Upside
Viatris Inc. stock logo
VTRS
Viatris
2.43
Hold$17.503.67% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
2.32
Hold$107.4341.91% Upside

Current Analyst Ratings Breakdown

Latest CRNX, ZTS, VTRS, and JAZZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Viatris Inc. stock logo
VTRS
Viatris
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
9/2/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/28/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$299.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$277.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$283.00 ➝ $322.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$300.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$287.00 ➝ $300.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$264.00 ➝ $281.00
8/26/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$292.00 ➝ $310.00
8/25/2026
Zoetis Inc. stock logo
ZTS
Zoetis
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$104.00 ➝ $94.00
8/25/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$94.00
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$7.70M1,170.54N/AN/A$11.23 per share7.56
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.27B3.75$16.26 per share15.18$71.07 per share3.47
Viatris Inc. stock logo
VTRS
Viatris
$14.30B1.36$7.37 per share2.29$12.77 per share1.32
Zoetis Inc. stock logo
ZTS
Zoetis
$9.47B3.30$7.55 per share10.02$7.56 per share10.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$465.32M-$5.04N/AN/AN/A-1,189.88%-44.22%-39.77%11/5/2026 (Estimated)
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M$14.5017.0211.130.2220.45%33.97%13.02%11/4/2026 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
-$3.51B-$0.36N/A6.351.52-2.79%20.02%8.02%11/5/2026 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$6.0712.4711.961.7727.49%74.89%18.59%11/3/2026 (Estimated)

Latest CRNX, ZTS, VTRS, and JAZZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Viatris Inc. stock logo
VTRS
Viatris
$0.6010$0.69+$0.0890-$0.10$3.68 billion$3.76 billion
8/6/2026Q2 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.85$1.87+$0.02$1.65$2.50 billion$2.47 billion
8/3/2026Q2 2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.18-$1.14+$0.04-$1.14$14.84 million$25.12 million
8/3/2026Q2 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$6.18$5.71-$0.47$2.78$1.11 billion$1.21 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
$0.482.84%N/AN/A N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.80%+20.11%34.93%14 Years

Latest CRNX, ZTS, VTRS, and JAZZ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/3/2026
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.122.94%8/21/20268/21/20269/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
15.57
15.53
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.69
1.78
1.58
Viatris Inc. stock logo
VTRS
Viatris
0.81
1.58
0.96
Zoetis Inc. stock logo
ZTS
Zoetis
2.87
3.08
1.84

Institutional Ownership

CompanyInstitutional Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Viatris Inc. stock logo
VTRS
Viatris
79.88%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.80%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.10%
Viatris Inc. stock logo
VTRS
Viatris
0.28%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
210106.10 million102.06 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89064.92 million62.25 millionOptionable
Viatris Inc. stock logo
VTRS
Viatris
30,0001.15 billion1.15 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500413.22 million412.32 millionOptionable

Recent News About These Companies

Amundi Increases Holdings in Zoetis Inc. $ZTS
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-increases-holdings-in-zoetis-inc-zts-2026-09-08/
Rep. Gilbert Ray Cisneros, Jr. Sells Off Zoetis Inc. (NYSE:ZTS) Stock
September 8 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-rep-gilbert-ray-cisneros-jr-sells-off-zoetis-inc-nyse-zts-stock-2026-09-08/
Nykredit A S Purchases New Shares in Zoetis Inc. $ZTS
September 6 at 4:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-purchases-new-shares-in-zoetis-inc-zts-2026-09-06/
Guardian Wealth Management Inc. Takes Position in Zoetis Inc. $ZTS
September 6 at 4:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-guardian-wealth-management-inc-takes-position-in-zoetis-inc-zts-2026-09-06/
Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of "Hold" by Brokerages
September 6 at 2:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005924
Zoetis Inc. (NYSE:ZTS) Given Average Rating of "Hold" by Brokerages
September 6 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-zoetis-inc-nyse-zts-given-average-rating-of-hold-by-brokerages-2026-09-06/
Zoetis Inc. $ZTS Holdings Cut by Raiffeisen Bank International AG
September 5 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-zoetis-inc-zts-holdings-cut-by-raiffeisen-bank-international-ag-2026-09-05/
AlphaGrep UK Ltd Buys New Position in Zoetis Inc. $ZTS
September 5 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphagrep-uk-ltd-buys-new-position-in-zoetis-inc-zts-2026-09-05/
AXQ Capital LP Takes $2.97 Million Position in Zoetis Inc. $ZTS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-takes-297-million-position-in-zoetis-inc-zts-2026-09-04/
B. Metzler seel. Sohn & Co. AG Trims Stock Holdings in Zoetis Inc. $ZTS
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-trims-stock-holdings-in-zoetis-inc-zts-2026-09-03/
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260902762857/en/zoetis-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Zoetis Inc. $ZTS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-decreases-holdings-in-zoetis-inc-zts-2026-09-01/
Public Employees Retirement System of Ohio Takes Position in Zoetis Inc. $ZTS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-takes-position-in-zoetis-inc-zts-2026-09-01/
Zoetis Inc. $ZTS Shares Purchased by Clifford Swan Investment Counsel LLC
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-zoetis-inc-zts-shares-purchased-by-clifford-swan-investment-counsel-llc-2026-09-01/
Kerrisdale Advisers LLC Acquires Shares of 42,000 Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-kerrisdale-advisers-llc-acquires-shares-of-42000-zoetis-inc-zts-2026-08-31/
Quantitative Investment Management LLC Purchases Shares of 45,119 Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantitative-investment-management-llc-purchases-shares-of-45119-zoetis-inc-zts-2026-08-31/
Moore Capital Management LP Acquires Shares of 202,749 Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moore-capital-management-lp-acquires-shares-of-202749-zoetis-inc-zts-2026-08-31/
Two Sigma Securities LLC Invests $3.05 Million in Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-invests-305-million-in-zoetis-inc-zts-2026-08-31/
Headlands Technologies LLC Acquires Shares of 55,106 Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-headlands-technologies-llc-acquires-shares-of-55106-zoetis-inc-zts-2026-08-31/
Benjamin Edwards Inc. Cuts Stake in Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-benjamin-edwards-inc-cuts-stake-in-zoetis-inc-zts-2026-08-31/
Flputnam Investment Management Co. Has $2.17 Million Stock Holdings in Zoetis Inc. $ZTS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flputnam-investment-management-co-has-217-million-stock-holdings-in-zoetis-inc-zts-2026-08-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)
As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$246.81 0.00 (0.00%)
Closing price 09/4/2026 04:00 PM Eastern
Extended Trading
$246.81 0.00 (0.00%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Viatris stock logo

Viatris NASDAQ:VTRS

$16.88 0.00 (0.00%)
Closing price 09/4/2026 04:00 PM Eastern
Extended Trading
$16.74 -0.15 (-0.86%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Zoetis stock logo

Zoetis NYSE:ZTS

$75.70 -0.11 (-0.15%)
Closing price 09/4/2026 03:58 PM Eastern
Extended Trading
$75.19 -0.51 (-0.67%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas